Advisory: Alerts on Epigenomics FY revenue, forecast withdrawn
28/03/2019 20:51
The alerts on Epigenomics' FY 2018 revenue, revision of sales
forecast are wrong and have been withdrawn. The alerts were
issued inadvertently from a research firm's press release.
Epigenomics reported FY 2018 results on March 27. For the
correct set of alerts, click urn:newsml:reuters.com:*:nFWN21E03O
STORY_NUMBER: FWN21F13C
STORY_DATE: 28/03/2019
STORY_TIME: 07:56:07
((Bengaluru Newsdesk: +1 646 223 8780))
Recent news on Epigenomics AG
See all newsU.S. FDA advisers back approval for Guardant's blood-based cancer test (updated)
U.S. FDA advisers back approval for Guardant's cancer test
Brief: Epigenomics Says Closing Of Agreement On The Acquisition Of Almost All Assets And Adjustment Of Guidance For 2023
Brief: Epigenomics AG Says It Entered Into Agreement On The Acquisition Of Almost All Assets With New Day Diagnostics LLC
Brief: Epigenomics Says Chief Scientific Officer Andrew Lukowiak Resigns